Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tenofovir Alafenamide Fumarate

FDA-approved product (tablet, oral), marketed as Tenofovir Alafenamide, Tenofovir Alafenamide Fumarate, Vemlidy.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tenofovir Alafenamide Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF13

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tenofovir Alafenamide Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tenofovir Alafenamide Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

    NCT07797231 · start 2026-09

    Registered record
    Registry ID
    NCT07797231
    Conditions
    Chronic Hepatitis B
    Interventions
    TQA3605 tablets Placebo; TQA3605 tablets; Entecavir dispersible tablets; Tenofovir Disoproxil Fumarate Tablets; Tenofovir Alafenamide Fumarate Tablets; Tenofovir Amibufenamide Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2029-10
    Enrolment
    930

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionTQA3605 tablets Placebo; TQA3605 tablets; Entecavir dispersible tablets; Tenofovir Disoproxil Fumarate Tablets +2 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach

    NCT07258251 · start 2026-01-01

    Registered record
    Registry ID
    NCT07258251
    Conditions
    Chronic Hepatitis B; Hepatitis B Virus Infection
    Interventions
    Tenofovir Alafenamide (TAF); Community-Based Support; Simplified WHO 2024 Criteria
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-01-01
    Completion
    2028-12-31
    Enrolment
    6,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B; Hepatitis B Virus Infection
    InterventionTenofovir Alafenamide (TAF); Community-Based Support; Simplified WHO 2024 Criteria
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

    NCT06337032 · start 2024-08-27

    Registered record
    Registry ID
    NCT06337032
    Conditions
    HIV-1-infection
    Interventions
    F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS); F/TAF (Low Dose TOS); F/TAF (Lowest Dose TOS); E/C/F/TAF; E/C/F/TAF (Low Dose); Cobicistat (High Dose); Cobicistat (Low Dose); Cobicistat (TOS); B/F/TAF (High Dose); B/F/TAF (Low Dose); B/F/TAF (High Dose TOS); B/F/TAF (Low Dose TOS); B/F/TAF (Lowest Dose TOS); 3rd ARV Agent; Nucleos(t)ide reverse transcriptase inhibitors (NRTI); ATV; DRV; Lopinavir Boosted with ritonavir (LPV/r)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-27
    Completion
    2034-03
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionF/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS) +17 more
    PhasePhase 4
    Registry statusRecruiting

  • Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.

    NCT07169656 · start 2024-06-03

    Registered record
    Registry ID
    NCT07169656
    Conditions
    Chronic Hepatitis b
    Interventions
    ETV,TDF,TAF,TMF; Peginterferon α-2b injection
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-06-03
    Completion
    2032-12-31
    Enrolment
    15,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis b
    InterventionETV,TDF,TAF,TMF; Peginterferon α-2b injection
    PhaseNot recorded
    Registry statusRecruiting

  • Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment

    NCT06221657 · start 2024-02-01

    Registered record
    Registry ID
    NCT06221657
    Conditions
    Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication
    Interventions
    Vemlidy; Virreal
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-02-01
    Completion
    2026-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication
    InterventionVemlidy; Virreal
    PhasePhase 4
    Registry statusNot yet recruiting

  • Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants

    NCT06278389 · start 2024-01-24

    Registered record
    Registry ID
    NCT06278389
    Conditions
    Healthy Adult Participants
    Interventions
    ACC017 tablets; Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-01-24
    Completion
    2024-05-20
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Participants
    InterventionACC017 tablets; Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
    PhasePhase 1
    Registry statusCompleted

  • The Effect Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Small Intestine Gut Wall

    NCT05326971 · start 2023-01-19

    Registered record
    Registry ID
    NCT05326971
    Conditions
    HIV Infections; Weight Gain
    Interventions
    gastroscopy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-01-19
    Completion
    2025-06-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Weight Gain
    Interventiongastroscopy
    PhasePhase 4
    Registry statusUnknown

  • Doravirine and Weight Gain in Antiretroviral Naive

    NCT05457530 · start 2022-08-01

    Registered record
    Registry ID
    NCT05457530
    Conditions
    Body Weight Changes; Human Immunodeficiency Virus; ART; Obesity; Minority Health; BMD; Metabolic Syndrome; Fasting
    Interventions
    DOR/3TC/TDF; DOR + FTC/TAF; BIC/FTC/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2022-08-01
    Completion
    2023-05-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBody Weight Changes; Human Immunodeficiency Virus; ART; Obesity +4 more
    InterventionDOR/3TC/TDF; DOR + FTC/TAF; BIC/FTC/TAF
    PhasePhase 3
    Registry statusWithdrawn

  • A Single and Multiple Ascending Dose Study of JNJ-64457744

    NCT05423106 · start 2022-07-04

    Registered record
    Registry ID
    NCT05423106
    Conditions
    Healthy; Hepatitis B, Chronic
    Interventions
    JNJ-64457744; Placebo; Tenofovir Disoproxil Fumarate (TDF); Tenofovir Alafenamide (TAF); Entecavir (ETV); JNJ-64457744
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-07-04
    Completion
    2023-03-20
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Hepatitis B, Chronic
    InterventionJNJ-64457744; Placebo; Tenofovir Disoproxil Fumarate (TDF); Tenofovir Alafenamide (TAF) +2 more
    PhasePhase 1
    Registry statusTerminated

  • A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

    NCT06707922 · start 2022-03-18

    Registered record
    Registry ID
    NCT06707922
    Conditions
    Chronic Hepatitis B
    Interventions
    Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2022-03-18
    Completion
    2029-07-31
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionPeginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • INSTI's For The Management of HIV-associated TB

    NCT04734652 · start 2022-02-18

    Registered record
    Registry ID
    NCT04734652
    Conditions
    HIV/AIDS; Tuberculosis, Pulmonary
    Interventions
    Biktarvy®; TLD- fixed-drug combination single tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-02-18
    Completion
    2024-08-31
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS; Tuberculosis, Pulmonary
    InterventionBiktarvy®; TLD- fixed-drug combination single tablet
    PhasePhase 2
    Registry statusCompleted

  • Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

    NCT05182463 · start 2022-01-08

    Registered record
    Registry ID
    NCT05182463
    Conditions
    Hepatitis B, Chronic
    Interventions
    Peginterferon Alfa-2B; Nucleoside Analogs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-01-08
    Completion
    2029-11-30
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionPeginterferon Alfa-2B; Nucleoside Analogs
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

    NCT06544551 · start 2021-12-28

    Registered record
    Registry ID
    NCT06544551
    Conditions
    Chronic Hepatitis B Virus Infection
    Interventions
    Peginterferon Alfacon-2; Peginterferon Alfacon-2 placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-12-28
    Completion
    2023-12-30
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B Virus Infection
    InterventionPeginterferon Alfacon-2; Peginterferon Alfacon-2 placebo
    PhasePhase 3
    Registry statusCompleted

  • Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

    NCT05122754 · start 2021-12-08

    Registered record
    Registry ID
    NCT05122754
    Conditions
    HIV-1-infection
    Interventions
    B/F/TAF; TDF-based triple ART regimen switching to B/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-12-08
    Completion
    2024-04-28
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionB/F/TAF; TDF-based triple ART regimen switching to B/F/TAF
    PhasePhase 4
    Registry statusUnknown

  • Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

    NCT04994509 · start 2021-08-30

    Registered record
    Registry ID
    NCT04994509
    Conditions
    Pre-Exposure Prophylaxis of HIV Infection
    Interventions
    Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN); F/TAF; F/TDF; Placebo SC LEN; PTM Oral LEN; PTM F/TAF; PTM F/TDF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-08-30
    Completion
    2028-01
    Enrolment
    5,368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-Exposure Prophylaxis of HIV Infection
    InterventionOral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN); F/TAF; F/TDF +4 more
    PhasePhase 3
    Registry statusActive not recruiting